Xilio Therapeutics, Inc.
General ticker "XLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $46.7M (TTM average)
Xilio Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -14.1%.
Estimated limits based on current volatility of 2.6%: low 8.30$, high 8.74$
Factors to consider:
- Total employees count: 64 (-12.3%) as of 2024
- Top business risk factors: Economic downturns and volatility, Manufacturing risks, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 12 months up through Q4 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.52$, 26.40$]
- 2025-12-31 to 2026-12-31 estimated range: [5.87$, 19.33$]
Financial Metrics affecting the XLO estimates:
- Negative: with PPE of -11.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -33.86 <= 0.07
- Positive: 19.49 < Shareholder equity ratio, % of 24.76 <= 42.60
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.07 > -0.65
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term XLO quotes
Long-term XLO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $6.34MM |
| Operating Expenses | $89.15MM | $79.13MM | $66.93MM |
| Operating Income | $-89.15MM | $-79.13MM | $-60.58MM |
| Non-Operating Income | $0.93MM | $2.73MM | $2.34MM |
| R&D Expense | $59.20MM | $52.14MM | $41.21MM |
| Income(Loss) | $-88.22MM | $-76.40MM | $-58.24MM |
| Profit(Loss)* | $-88.22MM | $-76.40MM | $-58.24MM |
| Stockholders Equity | $105.65MM | $36.83MM | $17.60MM |
| Assets | $139.16MM | $60.93MM | $71.08MM |
| Operating Cash Flow | $-75.72MM | $-68.62MM | $-18.38MM |
| Capital expenditure | $1.87MM | $0.49MM | $0.04MM |
| Investing Cash Flow | $-1.87MM | $-0.49MM | $-0.04MM |
| Financing Cash Flow | $-0.07MM | $-6.55MM | $29.20MM |
| Earnings Per Share** | $-45.09 | $-38.90 | $-15.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.